ClinicalTrials.gg
RecruitingNCT07316621PREDICT-CDUpdated Jul 29, 2026

Prospective Risk Evaluation and Detection of Crohn's Disease in First-degree Relatives

An observational study in Crohn Disease (CD), sponsored by GLSMED Learning Health S.A.. Recruiting at 10 sites in 6 countries. Open to participants aged 16 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by GLSMED Learning Health S.A. · Observational

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10,000
Ages
16 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 53 studies in Crohn Disease with a site in Portugal — 16 open to participants now, 23 under way, 15 of them phase 3. Crohn Disease · Portugal.

Started
2026
with 1 other
Observational
8 of 53
2 open now
Primary completion
2029-12
later than 17 of 22 live
Registered
52nd of 53
by date
Lead sponsor
3 of 53
GLSMED Learning Health S.A.

Among the 53 studies in Crohn Disease with a site in Portugal, this one is one of 2 that started in 2026, is one of 8 observational ones, reaches primary completion later than 17 of the 22 other live ones, and was the 52nd registered.

Crohn Disease

1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

16 of the 53 studies in Crohn Disease with a site in Portugal are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.

This study: 16 Years to 35 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Crohn Disease with a site in Portugal, or all of them as a file.
02

Study summary

The PREDICT-CD study aims to validate a risk score for the development of Crohn's disease, based on serological biomarkers and lifestyle-related factors. Given that having a family member with the disease is the strongest known risk factor, the target population will consist of first-degree relatives (aged 16 to 35) of individuals diagnosed with Crohn's disease.

This study will be conducted within Work Package 3 (WP3) of the INTERCEPT project, a consortium funded by the Innovative Health Initiative (IHI). The research will take place across 28 centres in seven countries: Portugal, Spain, France, Italy, the Netherlands, Sweden, and Poland.

To achieve the study objectives, individuals with Crohn's disease (referred to as patients) will be invited to participate and to engage their eligible first-degree relatives. At the baseline visit, the patient's physician will complete a clinical questionnaire covering disease history, treatments, and previous interventions.

At the same time, first-degree relatives (parents, siblings, or children) will donate a blood sample for serum isolation and, optionally, a whole blood and stool sample. They will also complete a questionnaire regarding their health status, habits, and preferences. Follow-up questionnaires will be administered every six months to monitor the onset of symptoms or behavioural changes.

03

Conditions studied

  • Crohn Disease (CD)

Browse trials for

04

Who can participate

Ages eligible
16 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The first-degree relative without a previous diagnosis of Inflammatory Bowel Disease

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants, between 16 and 35 years old
  • FDR (parent, full-siblings or offspring) from a patient with an established diagnosis of CD
  • Participants able to understand the information provided to them and to give written informed assent or consent for the study.

Exclusion criteria

Exclusion Criteria:

  • Prior diagnosis of IBD
  • Any legal or medical condition that limits the information and participation in the study
  • Inability to verify CD diagnosis in the proband
  • Participants unwilling or unable to provide informed written consent
  • Participants unwilling or unable to donate blood for serum
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • First-degree relatives
06

What researchers measure

Primary outcomes

  1. Development of Crohn's disease during the study period

    Diagnosis confirmed according to established diagnostic criteria, specifically endoscopy and histopathology

    Time frame: From enrolment until end of study follow-up (up to 3 years)

Secondary outcomes

  1. Proportion of first-degree relatives classified as high risk according to the PREDICT-CD risk prediction algorithm

    Proportion of enrolled first-degree relatives whose calculated risk score exceeds the predefined threshold for high-risk classification, based on the PREDICT-CD risk prediction algorithm incorporating serological biomarkers and lifestyle/environmental risk factors.

    Time frame: From enrolment until end of study follow-up (up to 3 years)

  2. Clinical and lifestyle characteristics of high-risk individuals who develop inflammatory bowel disease

    Characterization of high-risk participants who develop incident inflammatory bowel disease during follow-up, including: time from study enrolment to diagnosis; disease phenotype and disease behaviour at diagnosis; disease severity at diagnosis; early-life risk factors; dietary, nutritional and lifestyle factors; smoking exposure; medical and surgical history.

    Time frame: From enrolment until end of study follow-up (up to 3 years)

  3. Incidence of newly diagnosed immune-mediated inflammatory diseases other than Crohn's disease

    Number and proportion of participants diagnosed with a new immune-mediated inflammatory disease other than Crohn's disease during study follow-up, based on investigator-confirmed clinical diagnoses.

    Time frame: From enrolment until end of study follow-up (up to 3 years)

  4. Participant-reported willingness to receive predictive risk information and participate in preventive interventions

    Acceptability will be assessed using a study-specific participant questionnaire. The questionnaire will evaluate willingness to receive information regarding Crohn's disease risk, willingness to undergo additional monitoring, willingness to participate in disease-interception or prevention studies, and concerns and preferences related to predictive testing. Responses will be recorded as categorical and Likert-scale measures and summarized descriptively.

    Time frame: From enrolment until end of study follow-up (up to 3 years)

07

Study locations

10 of 10 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Dec 2029, 44 months after the start.

Of 232 non-industry observational studies under Crohn Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 101. This study's planned 44 months is close to that.

Counting every sponsor, half of 305 studies reached it within 41 months; a quarter within 29 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2025
First posted
Jan 5, 2026
StartActual
Apr 1, 2026
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2029
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07316621
Lead sponsor
GLSMED Learning Health S.A.
Responsible party
Sponsor
First posted
Jan 5, 2026
Start date
Apr 1, 2026
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Jul 29, 2026

Study contacts

Ana F Raimundo, PhD
Contact
intercept@hospitaldaluz.pt
+351 926139262

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion